17:17 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Mereo's BGS-649 meets in Phase IIb for hypogonadism

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase IIb trial in 271 obese men with hypogonadotropic hypogonadism showing that all three doses of once-weekly oral BGS-649 met the primary endpoint of normalizing...
16:51 , Dec 21, 2017 |  BC Innovations  |  Translation in Brief

Replacing the replacements

A Wake Forest team has developed a cell-based hormone replacement therapy that can control the hypothalamic-pituitary-ovarian axis with lower levels of estrogen than standard therapies, and could provide a solution to the side effects of...
21:45 , Sep 21, 2017 |  BC Innovations  |  Translation in Brief

Alphamab's soup

Chinese protein engineering company Alphamab is building a one-stop antibody production facility housing a slew of multispecific antibody-generating technologies and its own GMP plant under construction. The company has its own spin on the well-trodden...
17:50 , Jul 28, 2017 |  BC Week In Review  |  Financial News

Facio raises EUR4.8M in venture round

On June 20, facioscapulohumeral muscular dystrophy (FSHD) play Facio Therapies (Leiden, the Netherlands) raised €4.8 million ($5.6 million) in a venture round from Evotec AG (Xetra:EVT), patient organization Amis FSH and FSHD-affected families. Facio Therapies, Leiden,...
21:22 , May 26, 2017 |  BC Extra  |  Clinical News

FSH-blocking antibody could treat osteoporosis, obesity

Researchers at Icahn School of Medicine at Mount Sinai and other institutions showed that an antibody that blocks follicle stimulating hormone (FSH) increased bone mass and decreased body fat in a mouse model of menopause....
13:16 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

BGS-649: Ph IIb ongoing

An IDMC recommended continuation of a double-blind, placebo-controlled, international Phase IIb trial evaluating 3 doses of oral BGS-649 once weekly for 24 weeks based on an interim analysis conducted after the first 93 patients completed...
23:00 , Dec 14, 2016 |  BC Week In Review  |  Clinical News

Rekovelle regulatory update

Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland  Product: Rekovelle follitropin delta (FE 999049)  Business: Genitourinary  Ferring said the European Commission approved an MAA for Rekovelle follitropin delta for use in controlled ovarian stimulation to develop multiple follicles in women undergoing...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

KN015: Phase I started

Alphamab began an open-label, placebo-controlled, Chinese Phase I trial to evaluate a single dose of subcutaneous KN015 in about 70 healthy volunteers. Suzhou Alphamab Co. Ltd., Suzhou, China  Product: KN015  Business: Endocrine/Metabolic  Molecular target: NA  Description: Long-acting human follicle stimulating...
07:00 , Oct 24, 2016 |  BC Extra  |  Clinical News

Alphamab starts Phase I infertility study

Suzhou Alphamab Co. Ltd. (Suzhou, China) started a Chinese Phase I study of KN015, a long-acting human follicle stimulating hormone (FSH), to treat infertility. Compared with approved FSH treatments, which require multiple injections during a...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Follitropin delta: Phase III data

Top-line data from the single-blind, international Phase III ESTHER-1 trial in 1,326 women ages 18-40 undergoing their first cycle of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) showed that an individualized dosing regimen...